This article is more than 5 years old. Information may no longer be current.
EAACI calls for prioritization of allergic diseases in European politics
Click Here to Manage Email Alerts
The European Academy of Allergy and Clinical Immunology called for “an immediate concerted action” during its annual congress in Copenhagen to prioritize allergic diseases in the European political agenda.
“Allergy research remains a key need, for symptom control, understanding and prevention,” Nikolaos G. Papadopoulos, MD, PhD, EAACI president, said in a press release. “In addition, high-standard education and a common practice of the specialty is needed to allow free movement of patients and health care professionals across EU countries.”
Nikolaos G. Papadopoulos
EAACI called allergic diseases “a major epidemic” in Europe, with more than 150 million Europeans currently affected. That figure is expected to rise to 250 million in the next 10 years. The academy recently reinstated an office in Brussels that will act as a contact point for inquiries and “provide a platform to help place allergy higher on the EU agenda and translate policy opportunities into meaningful action,” the release said.
EAACI also has joined the European Chronic Disease Alliance and the Alliance for Biomedical Research in Europe to increase advocacy outreach and impact in its Brussels office. Other plans include establishing “allergy ambassadors” among EU parliament members and the development of an “EAACI Advocacy Manifesto,” according to the release.